FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2350778865> ?p ?o ?g. }

• W2350778865 abstract "Qingshuanmei (viper antithromboticenzyme) is a joinl product of Hospital 238 and Shenyang College of Pharmacy, It is a prepartion of enzyme which is extracted from snake venom of the terrestrial whir browed viper found in North East China, A series of pharmacological experiments has confirmed its following actions: Reduction of plasma fibrinogen, blood viscosity, platelet aggregation and adhesion; thrombolysis, vasodilation and improvement of the microcirculation, Hence it has marked anticoagulation effect and is effective in thrombotic disorders. Acute toxicity tests show a LD_(50) of 3.75±0.84u/kg when given intravenously. The clinically effective dose is 0.01-0.012u/kg. which is equivalent being 200.The drug may thus be considered safe. Subacute and chronic toxicity tests have confirmed that therapeutic doses have nodeleterious effects on cardiac, hepatic and renal function and are quite harmless. Pharmacokinetic data are: half life 4 hours; 90％ excretion in 24 hours, complete excretion in liver, Clinical observations of its use in more than 50000 cases in the past several years have demonstrated marked efficacy in more than 20 occlusive cerebral, cardiac, peripheral, fundal and other vascular diseases, efficacy rates being 9.23％ in 30000 cases of de cerebral thrombosis, 96％ in 524 cases of vasculitis, 98％ in 218 cases of deep phlebitis, and in 159 cases of coronary heart disease, the efficacy rate for angina was 96.2％ while that for, ischacmic ST—T changes in the EKG was 79.3％ Systematic clinical observations to date show that it gives good results in more than 20 conditions listed below: cerebral thrombosis, temporary ischaemic attacks (TIA), cerebral arteriosclerosis and dementia, paralysis agitans. Also has some effect on the sequelae of cerebral haemorrhage of more than 2 months duration; vasculitis, deep phlebitis, pulseless disease, Laynaud's disease, syndrome of superior and inforior vena caval obstructions; coronary heart disease, angina pectoris myocardial inforction; fundal arterial and venous thrombosis, abrupt deafness; anticoagulation in replantation of ampututed fingers and toes, scleroderma, dermatomyositis, systemic lupus erythematosus, scleredema neonatorum, hypercoagulation states, senilediahetes etc. The drug is given intaravenously ifter dilution in normal saline or glucose solution. It is administered once daily in a dose of 0.01～0.012u/kg. The usual adult dose is 0.5～0.75u 2—3 ampoules). A course lasts 15—20 days and may be repeated after an interval of 3—7 days. synergism is seen when it is combined with low molecular weight dextan. The drug is free from neurotoxic side effects such as vertigo, diplopia etc, and it does not reduce the blood platelel counl. Therapeutic doses are devoid of toxic side effects. Qingshuanmei is presetly an ideal drug for thrombotic diseases, which is highly effective, acts rapidly and causes few side effects." @default.
• W2350778865 created "2016-06-24" @default.
• W2350778865 creator A5036794047 @default.
• W2350778865 date "1989-01-01" @default.
• W2350778865 modified "2023-09-23" @default.
• W2350778865 title "THE CLINICAL APPLICATIONS OF QINGSHUANMEI (VIPER ANTITHROMBOTIC ENZYME)" @default.
• W2350778865 hasPublicationYear "1989" @default.
• W2350778865 type Work @default.
• W2350778865 sameAs 2350778865 @default.
• W2350778865 citedByCount "0" @default.
• W2350778865 crossrefType "journal-article" @default.
• W2350778865 hasAuthorship W2350778865A5036794047 @default.
• W2350778865 hasConcept C126322002 @default.
• W2350778865 hasConcept C164705383 @default.
• W2350778865 hasConcept C2777015399 @default.
• W2350778865 hasConcept C2779036427 @default.
• W2350778865 hasConcept C2780868729 @default.
• W2350778865 hasConcept C71924100 @default.
• W2350778865 hasConcept C98274493 @default.
• W2350778865 hasConceptScore W2350778865C126322002 @default.
• W2350778865 hasConceptScore W2350778865C164705383 @default.
• W2350778865 hasConceptScore W2350778865C2777015399 @default.
• W2350778865 hasConceptScore W2350778865C2779036427 @default.
• W2350778865 hasConceptScore W2350778865C2780868729 @default.
• W2350778865 hasConceptScore W2350778865C71924100 @default.
• W2350778865 hasConceptScore W2350778865C98274493 @default.
• W2350778865 hasOpenAccess W2350778865 @default.
• W2350778865 hasRelatedWork W1513181289 @default.
• W2350778865 hasRelatedWork W1545135833 @default.
• W2350778865 hasRelatedWork W1985374860 @default.
• W2350778865 hasRelatedWork W1997731509 @default.
• W2350778865 hasRelatedWork W2010809772 @default.
• W2350778865 hasRelatedWork W2041260232 @default.
• W2350778865 hasRelatedWork W2051411327 @default.
• W2350778865 hasRelatedWork W2092414645 @default.
• W2350778865 hasRelatedWork W2093001405 @default.
• W2350778865 hasRelatedWork W2121490283 @default.
• W2350778865 hasRelatedWork W2137008211 @default.
• W2350778865 hasRelatedWork W2219674570 @default.
• W2350778865 hasRelatedWork W2241172575 @default.
• W2350778865 hasRelatedWork W2390947289 @default.
• W2350778865 hasRelatedWork W2399946497 @default.
• W2350778865 hasRelatedWork W2401358364 @default.
• W2350778865 hasRelatedWork W2401608642 @default.
• W2350778865 hasRelatedWork W2521512935 @default.
• W2350778865 hasRelatedWork W2895060950 @default.
• W2350778865 hasRelatedWork W3140236318 @default.
• W2350778865 isParatext "false" @default.
• W2350778865 isRetracted "false" @default.
• W2350778865 magId "2350778865" @default.
• W2350778865 workType "article" @default.